Transducer of erbB2.1 is a potential cellular target of gefitinib in lung cancer therapy

Oncology Letters

Volumn 5, Issue 1, 2012, Pages 373-377

  Sun, Ke Kang ^a,b   Yang, Yang ^b   Zhao, Lin ^b   Wang, Li Li ^b   Jiao, Yang ^b  

^a KUNSHAN FIRST PEOPLE S HOSPITAL AFFILIATED TO JIANGSU UNIVERSITY   (China)

^b MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

Author keywords

Cyclin D1; Gefitinib; Lung cancer; Transducer of erbB2.1 (TOB1)

Indexed keywords

CYCLIN D1; GEFITINIB; PROTEIN; TRANSDUCER OF ERBB2.1; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; GENE SILENCING; HUMAN; HUMAN CELL; LUNG CARCINOMA; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE;

EID: 84869044625     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.969     Document Type: Article

References (25)

1. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CACancer J Clin 2: 69-90, 2011.
2. Inamura K and Ishikawa Y: Lung cancer progression and metastasis from the prognostic point of view. Clin Exp Metastasis6: 389-397, 2010.
3. Wakeling AE, Guy SP, Woodburn JR, et al: ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62: 5749-5754, 2002.
4. Ciardiello F: Epidermal growth factor receptor inhibitors in cancer treatment. Future Oncol 1: 221-234, 2005.
5. Maione P, Gridelli C, Troiani T, et al: Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC. Oncologist 11: 274-284, 2006.
6. Polychronis A, Sinnett HD, Hadjiminas D, et al: Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. Lancet Oncol 6: 383-391, 2005.
7. Montemurro F, Valabrega G and Aglietta M: Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. Expert Opin Biol Ther 7: 257-268, 2007.
8. Ranson M, Hammond LA, Ferry D, et al: ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 20: 2240-2250, 2002.
9. Krol J, Francis RE, Albergaria A, et al: The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells. Mol Cancer Ther 6: 3169-3179, 2007.
10. Matsuda S, Kawamura-Tsuzuku J, Ohsugi M, et al: Tob, a novel protein that interacts with p185erb B2, is associated with anti-proliferative activity. Oncogene 4: 705-713, 1996.
11. Winkler GS: The mammalian anti-proliferative BTG/Tob protein family. J Cell Physiol 1: 66-72, 2010.
12. Wang XM, Gao X, Zhang XH, et al: The negative cell cycle regulator, Tob (transducer of ErbB-2), is involved in motor skill learning. Biochem Biophys Res Commun 4: 1023-1027, 2006.
13. Jia S and Meng A: Tob genes in development and homeostasis. Dev Dyn 4: 913-921, 2007.
14. Helms MW, Kemming D, Contag CH, et al: TOB1 is regulated by EGF-dependent HER2 and EGFR signaling, is highly phosphorylated, and indicates poor prognosis in node-negative breast cancer. Cancer Res 12: 5049-5056, 2009.
15. Jiao Y, Sun KK, Zhao L, et al: Suppression of human lung cancer cell proliferation and metastasis in vitro by the transducer of ErbB-2.1 (TOB1). Acta Pharmacol Sin 33: 250-260, 2012.
16. Astsaturov I, Cohen RB and Harari P: Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer. Expert Rev Anticancer Ther 6: 1179-1193, 2006.
17. Scaltriti M and Baselga J: The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 12: 5268-5272, 2006.
18. Johnston JB, Navaratnam S, Pitz MW, et al: Targeting the EGFR pathway for cancer therapy. Curr Med Chem 13: 3483-3492, 2006.
19. Uchida A, Hirano S, Kitao H, et al: Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation. Cancer Sci 98: 357-363, 2007.
20. Iwanaga K, Sueoka N, Sato A, et al: Alteration of expression or phosphorylation status of tob, a novel tumor suppressor gene product, is an early event in lung cancer. Cancer Lett 1: 71-79, 2003.
21. Ito Y, Suzuki T, Yoshida H, et al: Phosphorylation and inactivation of Tob contributes to the progression of papillary carcinoma of the thyroid. Cancer Lett 2: 237-242, 2005.
22. Yanagie H, Tanabe T, Sumimoto H, et al: Tumor growth suppression by adenovirus-mediated introduction of a cell-growth-suppressing gene tob in a pancreatic cancer model. Biomed Pharmacother 4: 275-286, 2009.
23. Lapenna S and Giordano A: Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 8: 547-566, 2009.
24. Felsher DW: Cancer revoked: oncogenes as therapeutic targets. Nat Rev Cancer 3: 375-380, 2003.
25. Suzuki T, K-Tsuzuku J, Ajima R, et al: Phosphorylation of three regulatory serines of Tob by Erk1 and Erk2 is required for Ras-mediated cell proliferation and transformation. Genes Dev11: 1356-1370, 2002.